Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$89.51 USD
+0.69 (0.78%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $89.55 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Earnings News For GILD
-
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
-
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
-
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
-
Gilead: Q2 Earnings Snapshot
-
Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
-
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
-
Gilead: Q1 Earnings Snapshot
-
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
-
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
-
Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?
-
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
-
Gilead: Q4 Earnings Snapshot
-
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
-
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
-
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
-
Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales
-
Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates
-
Gilead: Q3 Earnings Snapshot
-
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
-
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
-
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
-
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
-
Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?
-
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge